Inhibikase Therapeutics (IKT) Non-Current Debt (2020 - 2021)

Inhibikase Therapeutics (IKT) reported Non-Current Debt of $248911.0 for Q2 2021, little changed quarter-over-quarter from $248911.0 in Q1 2021.

Inhibikase Therapeutics (IKT) Non-Current Debt (2020 - 2021) Analysis & Trends

Inhibikase Therapeutics (IKT) has 2 years of Non-Current Debt data on file, last reported at $248911.0 in Q2 2021.

Non-Current Debt for Q2 2021 came in at $248911.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2021 was $248911.0 (changed N/A YoY), and the FY2020 annual result was $276461.0, changed N/A from the prior year.
Non-Current Debt steadied at $248911.0 in Q2 2021 per IKT's latest filing, from $248911.0 in the prior quarter.
Over five years, Non-Current Debt peaked at $276461.0 in Q4 2020 and troughed at $248911.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	319.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Inhibikase Therapeutics	285.17 Mn	114.80 Mn	-	-

Download Data